4.96
-0.08(-1.59%)
Currency In USD
| Previous Close | 5.04 |
| Open | 5.02 |
| Day High | 5.34 |
| Day Low | 4.96 |
| 52-Week High | 5.66 |
| 52-Week Low | 1.29 |
| Volume | 5.1M |
| Average Volume | 2.48M |
| Market Cap | 593.19M |
| PE | -3.52 |
| EPS | -1.41 |
| Moving Average 50 Days | 3.53 |
| Moving Average 200 Days | 2.6 |
| Change | -0.08 |
If you invested $1000 in Annexon, Inc. (ANNX) since IPO date, it would be worth $279.28 as of December 14, 2025 at a share price of $4.96. Whereas If you bought $1000 worth of Annexon, Inc. (ANNX) shares 3 years ago, it would be worth $895.31 as of December 14, 2025 at a share price of $4.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
GlobeNewswire Inc.
Nov 14, 2025 9:01 PM GMT
BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 13, 2025 3:55 AM GMT
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 12, 2025 9:12 PM GMT
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain,